BioCentury | Nov 16, 2019
Regulation

Stephen Hahn’s road to White Oak

The path to Stephen Hahn’s confirmation as FDA commissioner is enveloped in clouds of flavored vapor, littered with piles of Impossible Burgers, and passes tanks filled with precocious fish. The Trump administration’s policies on regulating...
BC Extra | Aug 19, 2019
Clinical News

Aug. 19 Clinical Quick Takes: Kalytera's cannabidiol shows promise for transplant, plus Abbisko and Brigham and Women's

Kalytera's CBD prevents graft-vs-host disease  Kalytera Therapeutics Inc. (TSX-V:KLY; OTCQB:KALTF) announced plans to start a Phase III registrational trial of cannabidiol after low and medium doses reduced the incidence of Grade 2-4 acute graft-versus-host disease...
BC Innovations | Apr 2, 2019
Distillery Therapeutics

OPN1MW gene therapy for retinitis pigmentosa

DISEASE CATEGORY: Ophthalmic disease INDICATION: Retinitis Mouse studies suggest OPN1MW gene therapy could help treat retinitis pigmentosa. In a mouse model of retinitis pigmentosa, intravitreal injection of the mouse homolog of OPN1MW encoded in an...
BioCentury | Mar 27, 2019
Product Development

GW’s next act

As Epidiolex’s launch continues to ramp up, GW Pharmaceuticals’ next act will be to take the plunge with its cannabinoid platform into larger, more complex neurobehavioral indications, and even cancer. Not surprisingly, the rise of...
BC Week In Review | Mar 1, 2019
Company News

GW gains on first sales figure for Epidiolex

GW Pharmaceuticals plc (NASDAQ:GWPH) added $21.10 (14%) to $173.99 on Feb. 27 after reporting that sales of Epidiolex cannabidiol reached $4.7 million in the two-month period since the marijuana-derived drug's launch on Nov. 1. FDA...
BC Extra | Feb 27, 2019
Company News

GW gains on first sales figure for Epidiolex

GW Pharmaceuticals plc (NASDAQ:GWPH) added $21.10 (14%) to $173.99 on Wednesday after reporting that sales of Epidiolex cannabidiol reached $4.7 million in the two-month period since the marijuana-derived drug's launch on Nov. 1. FDA approved...
BC Week In Review | Oct 26, 2018
Company News

Stanford launches cannabinoid company Katexco for inflammatory disorders

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco has exclusively licensed IP from the university. The IP was generated by...
BC Week In Review | Oct 5, 2018
Financial News

GW raises $345M follow-on

GW Pharmaceuticals plc (NASDAQ:GWPH) raised $345 million through the sale of 2.2 million ADSs at $158 in a follow-on underwritten by Goldman Sachs, Morgan Stanley and J.P. Morgan. The offering includes a 285,000 share overallotment...
BC Extra | Oct 3, 2018
Financial News

GW, Epizyme, Kala price follow-ons

GW Pharmaceuticals plc (NASDAQ:GWPH), Epizyme Inc. (NASDAQ:EPZM) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) each priced follow-ons late Tuesday, raising a total of $437 million. GW raised $300 million through the sale of 1.9 million ADSs at...
BC Week In Review | Sep 28, 2018
Company News

GW to launch Epidiolex in U.S. following DEA reschedule

GW Pharmaceuticals plc (NASDAQ:GWPH) said the U.S. Drug Enforcement Agency has rescheduled Epidiolex cannabidiol to schedule V, the lowest restriction classification, from a schedule I, clearing the way for GW to launch the drug in...
Items per page:
1 - 10 of 151